(22 May 2026, Hong Kong) – Templewater is pleased to share that one of its portfolio companies, Tamarind Health, Asia’s leading integrated oncology-focused group, has completed the acquisition of Hong Kong Women’s Imaging Limited, Hong Kong MRI Limited, Hong Kong Medical Imaging Limited and their related affiliates (together, the “HKWI Group”) in Hong Kong. This milestone advances Tamarind Health’s strategy to build Asia’s leading integrated oncology-focused platform, with a growing focus on a connected and comprehensive organ-specific care model across the region.
Founded by Dr Fong Chun Yan and Dr Lui Chun Ying, HKWI Group has established itself as a leading diagnostic imaging group in Hong Kong, with a strong reputation in women’s and general imaging. Over the years, the Group has built trusted relationships with referring doctors and patients through its consistent focus on clinical quality, patientcare and medical excellence.
The addition of HKWI Group brings together two leaders — uniting Hong Kong’s leading radiology specialists with Tamarind Health’s oncology expertise through OncoCare (Hong Kong), Tamarind Health’s oncology specialist clinic in Hong Kong. This forms an integrated ecosystem which we believe will enhance patients’ journey, experience and outcomes. HKWI Group is an ideal partner for OncoCare (Hong Kong) across the full patient journey, from early detection and diagnosis to treatment planning, monitoring and survivorship. The combined network now operates nine clinics and imaging centres across Hong Kong, connecting more than 22 specialists across radiology, surgery and oncology. This further strengthens Tamarind Health’s presence in the city and supports its ambition to build an integrated breast care model across Asia.
Tamarind Health already operates Solis and Luma, one of the largest private integrated breast care centres in Singapore, and with the addition of HKWI Group, we are well positioned to continue to deliver thought leadership on an integrated care-focused model across Asia.
With the integration of HKWI Group, patients will be better served through multidisciplinary collaboration among oncologists, surgeons and radiologists across its regional network. The acquisition also lays the foundation for the progressive development of a centre of excellence for breast care in Hong Kong.
Lim Eng Seng, Group CEO of Tamarind Health, said: “Breast cancer cases continue to rise globally, and we see a strong opportunity to build a more integrated and patient-centric breast care model across Asia. HKWI Group’s proven clinical strength and commitment to patient care make them an ideal partner for this journey in Hong Kong.”
Dr Fong Chun Yan said: “We are proud of what the team at HKWI Group has built over the years and are excited to join Tamarind Health for our next phase of growth. We share a common commitment to delivering high-quality, patient-centred care and believe this partnership will create meaningful opportunities to further strengthen breast imaging and enhance multidisciplinary care.”
Dr Lui Chun Ying added: “Joining Tamarind Health allows us to become part of a broader regional network of specialists while maintaining the standards trusted by our patients and referring doctors. We look forward to working closely with the Tamarind Health team, their oncologists and surgeons to improve diagnostic accuracy, accelerate clinical decision-making and support patients more effectively.”
About Tamarind Health
Tamarind Health is Asia’s leading integrated oncology-focused group, uniting renowned practices across the region to elevate care and improve patient outcomes. Headquartered in Singapore, the doctor-led platform brings together specialists across the full spectrum of oncology, from diagnostics and treatment to survivorship and well-being.
Our journey began with the acquisition of OncoCare Singapore and Novena Heart Centre, laying the foundation of our oncology and cardiac expertise. This foundation was broadened with Solis, Luma, OncoCare Philippines, and Can-Care, expanding our focus into breast care and post-care services. The network subsequently grew to include OncoCare Malaysia, OncoCare Hong Kong, and Tamarind Specialists, strengthening our regional presence. The group’s network also includes TalkMED in Singapore. With the addition of HKWI Group, Tamarind Health continues to strengthen its integrated, organ-specific care model across the region.
With the purpose of setting new standards in healthcare for better results, Tamarind Health is shaping the future of oncology and related services across six markets: Singapore, Hong Kong, Malaysia, the Philippines, Vietnam, and Mainland China.
We Believe in Better.
For more information, visit: https://tamarindhealth.com
